Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus
机构:[1]Department of Rheumatology, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, China[2]Department of Rheumatology, the Affiliated Hospital of Bengbu Medical College, China[3]Department of Rheumatology, theFourth People’s Hospital of Shenzhen Affiliated to Guangdong Medical College, China深圳市康宁医院深圳医学信息中心[4]Department of Rheumatology, Beijing Children HospitalAffiliated to Capital Medical University, China首都医科大学附属北京儿童医院[5]Department of Rheumatology, the Second Hospital of Shanxi Medical University, China[6]Department of Clinical Immunology and Rheumatology, Xijing Hospital affiliated to the Fourth Military Medical University, China[7]Department of Rheumatology, Beijing Tongren Hospital affiliated to Capital Medical University, China临床科室风湿免疫科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[8]Department of Rheumatology, BeijingChao-Yang Hospital affiliated to Capital Medical University, China北京朝阳医院[9]Department of Rheumatology, Anhui Provincial Hospital, China[10]Department of Rheumatology, Jiangsu Provincial People’s Hospital, China[11]Department of Cardiology, Peking Union Medical CollegeHospital, China[12]Pulmonary Vascular Center, Fu Wai Cardiovascular Hospital, China
Objectives: To estimate the prevalence of pulmonary arterial hypertension (PAH) and risk factors for PAH in patients registered in the Chinese SLE Treatment and Research group (CSTAR) database, the first online registry of Chinese patients with systemic lupus erythematosus (SLE). Methods: A prospective cross-sectional study of patients with SLE was conducted using the CSTAR registry. Resting transthoracic echocardiography was used to estimate pulmonary artery pressure (PAP); PAH was defined as systolic PAP (PASP) >= 40 mmHg. Patients with interstitial lung disease, valvular disease or cardiomyopathy were excluded because of disease influence on PAP. We explored potential risk factors for PAH including patient characteristics, organ involvement, laboratory findings and SLE disease activity. Results: Of 1934 patients with SLE, 74 had PASP with 54.2 +/- 17.1 (40,106) mmHg and were diagnosed with probable PAH. The incidences of lupus nephritis, pleuritis, pericarditis, hypocomplementemia, anti-SSA, and anti-ribonucleoprotein (RNP) were significantly higher in patients with PAH than in those without (p<0.05). SLE disease activity was significantly higher in patients with PAH than in unaffected patients (p<0.05). Multivariate analysis indicated that pericarditis (odds ratio (OR) = 4.248), pleuritis (OR = 3.061) and anti-RNP (OR = 2.559) were independent risk factors for PAH in patients with SLE (p<0.05). Conclusions: The possible prevalence of PAH was 3.8% in Chinese patients with SLE in the CSTAR registry. The significant association of pericarditis, pleuritis and anti-RNP positivity with PAH suggests that higher disease activity and vasculopathy may both contribute to the development of PAH in SLE, which need be treated aggressively to improve prognosis.
基金:
Chinese National
Key Technology R&D Program, Ministry of
Science and Technology (2008BAI59B02,
2011BAI11B15), the Chinese National High
Technology Research and Development Program,
Ministry of Science and Technology
(2012AA02A513), the Research Special Fund for
Public Welfare Industry of Health, Ministry of
Health (201202004) and National Major Scientific
and Technological Special Project for ‘‘Significant New Drugs Development’’ Ministry of Science and
Technology (2012ZX09303006-002).
第一作者机构:[1]Department of Rheumatology, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, China
共同第一作者:
通讯机构:[*1]Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
推荐引用方式(GB/T 7714):
M Li,Q Wang,J Zhao,et al.Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus[J].LUPUS.2014,23(10):1085-1091.doi:10.1177/0961203314527366.
APA:
M Li,Q Wang,J Zhao,Z Li,Z Ye...&CSTAR co-authors.(2014).Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus.LUPUS,23,(10)
MLA:
M Li,et al."Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus".LUPUS 23..10(2014):1085-1091